Google's Gemini 4 Carbon outranks GPT-6 and Claude

PLUS: NVIDIA opens Nemotron 3.5 Transcribe for 40 languages & Anthropic ships Claude for Legal tools. ChatGPT plugs into iCloud Mail and Calendar, Anthropic buys solo biotech Mithril Medicine.

1️⃣ Google launches Gemini 4 Carbon, scoring 59 on the Intelligence Index, with access limited to cyber defenders

2️⃣ NVIDIA releases open-weight Nemotron 3.5 Transcribe for 40 languages, plus Granary v2 pipelines

3️⃣ Anthropic rolls out Claude for Legal, built with help from Harvey and Legora

  • ChatGPT connects to iCloud Mail and iCloud Calendar on all plans

  • Anthropic acquires Mithril Medicine, targeting human trials by late 2028

MAIN AI UPDATES / 29th October 2026

🤖 Google's Gemini 4 Carbon outranks GPT-6 and Claude 🤖
Access is limited, for now, to select cyber defenders.

Google has launched Gemini 4 Carbon, a frontier model that scores 59 on Artificial Analysis' Intelligence Index, placing it ahead of Claude Opus 5.5 and GPT-6 Astra. The model targets two demanding areas: cybersecurity and long-running coding work, tasks that require sustained reasoning over many steps. Instead of a broad public release, Google is limiting initial access to select cyber defenders, a cautious move given how easily offensive security capabilities can be misused. The ranking puts fresh competitive pressure on OpenAI and Anthropic at the top of the leaderboard. For developers and enterprises, the open question is when Gemini 4 Carbon reaches the Gemini API and at what price.

🤖 NVIDIA opens Nemotron 3.5 Transcribe for 40 languages 🤖
Open weights give developers access, integration and fine-tuning freedom.

NVIDIA has released Nemotron 3.5 Transcribe, an open-weight model that handles multilingual transcription, translation, speaker attribution and audio Q&A across up to 40 languages. Rather than stitching together separate tools for each task, developers get a single model that can turn a meeting recording into a translated, speaker-labelled transcript and then answer questions about it. The release ships alongside Granary v2, a set of data pipelines for fine-tuning, so teams can adapt the model to their own accents, jargon or industries. Because the weights are open, companies can run it on their own infrastructure, which matters for privacy-sensitive sectors like healthcare. It also adds pricing pressure on paid speech APIs from rivals.

🤖 Anthropic ships Claude for Legal tools 🤖
Integration with Legora brings Claude straight into lawyers' workflows.

Anthropic has launched Claude for Legal, a set of ready-made tools built for three of the most time-consuming tasks in law: contract review, regulatory monitoring and cite checks. Instead of writing prompts from scratch, lawyers can open a purpose-built tool and get structured output they can verify and reuse. Anthropic did not build everything alone: Harvey, one of the best-known legal AI startups, helped develop one of the tools, while Legora joins as an integration partner. The partnerships signal that Anthropic sees legal specialists as distribution channels, not only rivals. With Claude for Legal, Anthropic moves deeper into regulated professional services, a high-value market where accuracy and citations decide adoption.

INTERESTING TO KNOW

📱 ChatGPT plugs into iCloud Mail and Calendar 📱

OpenAI is rolling out ChatGPT plugins for iCloud Mail and iCloud Calendar, with access on all ChatGPT plans, including the free tier. Users can now ask ChatGPT questions about their emails or create calendar events directly from a conversation, without switching apps. Bringing Apple's email and calendar into ChatGPT widens its distribution among iPhone users and deepens its role as a daily assistant.

🧬 Anthropic buys solo biotech Mithril Medicine 🧬

Anthropic has acquired Mithril Medicine, the solo-founder biotech of Cody Tranbarger, in a deal that highlights the speed at which one researcher using Claude can advance a therapy. Its Claude-assisted muscular dystrophy candidate could reach human trials by late 2028. For Anthropic, the deal is a concrete adoption signal for Claude in life sciences and drug discovery.

📩 Have questions or feedback? Just reply to this email , we’d love to hear from you!

🔗 Stay connected: